Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY2181308 + docetaxel
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
LY2181308 + docetaxel is a combination therapy consisting of LY2181308, an antisense oligonucleotide targeting survivin mRNA, and docetaxel, a taxane-class chemotherapeutic agent. LY2181308 inhibits the expression of survivin, an antiapoptotic protein overexpressed in various cancers and associated with resistance to chemotherapy. By downregulating survivin, LY2181308 aims to restore apoptosis in tumor cells and enhance the cytotoxic effects of chemotherapy. Docetaxel disrupts microtubule function during cell division, leading to cell death. This combination has been investigated primarily for its potential to improve outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and castration-resistant prostate cancer (CRPC), but clinical trials have not demonstrated significant efficacy improvements over standard therapies[1][2][5].
02
Targets
BIRC5 (Survivin)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on LY2181308 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY2181308 + docetaxel.